Department of Medical Biotechnology, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull HU3 2JZ, UK.
Pharmacol Res. 2020 Mar;153:104662. doi: 10.1016/j.phrs.2020.104662. Epub 2020 Jan 23.
MicroRNAs (miRNA) are one class of the small regulatory RNAs that can impact the expression of numerous genes including incretin hormones and their G protein-coupled receptors. Incretin peptides, including GLP-1, GLP-2, and GIP, are released from the gastrointestinal tract and have an crucial role in the glucose hemostasis and pancreatic beta-cell function. These hormones and their analogs with a longer half-life, glucagon like peptide-1 receptor agonists (GLP1RA), modify the expression of miRNAs. Dipeptidyl peptidase IV (DPP-4) is an enzyme that degrades the incretin hormones and is inactivated by DPP-4 inhibitors, which are a class of compounds used in the management of type 2 diabetes. DPP-4 inhibitors may also increase or reduce the expression of miRNAs. In this review, we describe the possible interactions between miRNAs and incretin hormones and the relevance of such interactions to physiological processes and diseases.
微小 RNA（miRNA）是一类小的调节 RNA，可以影响包括肠促胰岛素激素及其 G 蛋白偶联受体在内的众多基因的表达。肠促胰岛素肽，包括 GLP-1、GLP-2 和 GIP，从胃肠道释放出来，在葡萄糖止血和胰腺β细胞功能中起着至关重要的作用。这些激素及其半衰期较长的类似物，胰高血糖素样肽-1 受体激动剂（GLP1RA），可调节 miRNA 的表达。二肽基肽酶 4（DPP-4）是一种可降解肠促胰岛素激素的酶，可被 DPP-4 抑制剂失活，DPP-4 抑制剂是用于治疗 2 型糖尿病的一类化合物。DPP-4 抑制剂也可能增加或减少 miRNA 的表达。在这篇综述中，我们描述了 miRNA 和肠促胰岛素激素之间可能存在的相互作用，以及这种相互作用与生理过程和疾病的相关性。
